Table 4.

Sociodemographic and Treatment Characteristics of Participants With Tumor Involvement of the HP Region

Variable	Participants (n = 77)
	No.	%
Sex
Male	44	57.1
Female	33	42.9
Race/ethnicity
Non-Hispanic white	63	81.8
Non-Hispanic black	12	15.6
Other	2	2.6
Age at tumor diagnosis, median (range), y	8.3 (0.4–17.8)
Age at SJLIFE, median (range), y	25.3 (19.2–40.5)
Primary tumor diagnosis
Craniopharyngioma	26	33.8
Glial cell tumor	46	59.7
Other CNS tumor	5	6.5
Stroke
Yes	12	15.6
No	65	84.4
Seizure
Yes	20	26.0
No	57	74.0
Hydrocephalus with shunt placement
Yes	25	32.5
No	52	67.5
HP dose, Gy
No cranial RT	37	48.1
1–19.9	0	0
20–30	0	0
>30	40	51.9
Alkylating agent
Yes	4	5.2
No	73	94.8
Intrathecal chemotherapy
Yes	0	0
No	77	100
HP disorder present at tumor diagnosis
Yes	37	48.1
One HP disorder	15	40.5
Multiple HP disorders	22	59.5
No HP disorder	40	51.9

Abbreviation: RT, radiation therapy.